Signaling Pathway
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
| Discription | LJI308 is a new and potent pan-RSK inhibitor, with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. | ||
|---|---|---|---|
| Targets |
|
| Catalog Num | A14373 |
|---|---|
| Formula | C21H18F2N2O2 |
| Molecular Weight | 368.38 |
| CAS Number | 1627709-94-7 |
| SMILES | OC1=C(F)C=C(C2=C(C3=CC=C(N4CCOCC4)C=C3)C=CN=C2)C=C1F |
| Synonyms | LJI 308, LJI-30 |
| Storage | Store lyophilized at -20ºC, keep desiccated. |
| In vitro | DMSO | Warmed: 66 mg/mL (179.16 mM) | |
| Water | Insoluble | ||
| Ethanol | Insoluble | ||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 27.15 mL | 135.73 mL | 271.46 mL |
| 0.5 mM | 5.43 mL | 27.15 mL | 54.29 mL |
| 1 mM | 2.71 mL | 13.57 mL | 27.15 mL |
| 5 mM | 0.54 mL | 2.71 mL | 5.43 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
